Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Exenatide tQT clinical trial meets pre-specified primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes